TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
Join us at the World Vaccine Congress next week as we showcase our latest breakthrough in mRNA-LNP stability, TheraPHIX™! We’re thrilled that our CEO, Andrew Goldsborough will be speaking on 31st October at 10am in Theatre 6. His talk, *"TheraPHIX™ technology for ambient temperature liquid-stable mRNA-LNP therapeutics and vaccines"* will delve into how we’re reshaping the future of vaccine delivery and therapeutic stability.
RNAssist is proud to announce the development of TheraPHIX™, a groundbreaking solution in mRNA vaccine stability. In collaboration with the Centre for Process Innovation (CPI) and with funding from Innovate UK, we have successfully created an ambient temperature liquid-stable mRNA-LNP formulation.
Single-cell RNA sequencing presents an opportunity to deconstruct cellular networks but is limited by the loss of biological information. In this study, a new method of fixation before dissociation using a deep eutectic solvent (DES) is presented.
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com